Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness

Lung Cancer

Volumn 101, Issue , 2016, Pages 98-103

  Goffin, John R ^a   Flanagan, William M ^b   Miller, Anthony B ^c   Fitzgerald, Natalie R ^d   Memon, Saima ^d   Wolfson, Michael C ^e   Evans, William K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b STATISTICS CANADA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Canadian Partnership Against Cancer   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cost effectiveness; Low dose CT; Lung cancer; Screening; Smoking cessation

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; HEALTH SURVEY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK MANAGEMENT; SMOKING CESSATION; CANADA; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ECONOMICS; EPIDEMIOLOGY; FEMALE; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; RADIATION DOSE; SMOKING; X-RAY COMPUTED TOMOGRAPHY;

AGED; CANADA; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RADIATION DOSAGE; SMOKING; SMOKING CESSATION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84989170605     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.09.013     Document Type: Article

References (21)

1. [1] Canadian Partnership Against Canada, Lung Cancer in Canada: a Supplemental System Performance Report, Toronto, 2011, pp. 15–16. https://content.cancerview.ca/download/cv/quality_and_planning/system_performance/documents/cpac015706pdf?attachment=0.
2. [2] Danaei, G., Vander Hoorn, S., Lopez, A.D., Murray, C.J., Ezzati, M., Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366:9499 (2005), 1784–1793.
3. [3] Goldstraw, P., Crowley, J., Chansky, K., Giroux, D.J., Groome, P.A., Rami-Porta, R., Postmus, P.E., Rusch, V., Sobin, L., The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2:8 (2007), 706–714.
4. [4] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA Cancer J. Clin. 62:1 (2012), 10–29.
5. [5] Aberle, D.R., Adams, A.M., Berg, C.D., Black, W.C., Clapp, J.D., Fagerstrom, R.M., Gareen, I.F., Gatsonis, C., Marcus, P.M., Sicks, J.D., Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365:5 (2011), 395–409.
6. [6] King, B.A., Dube, S.R., Babb, S.D., McAfee, T.A., Patient-reported recall of smoking cessation interventions from a health professional. Prev. Med. 57:5 (2013), 715–717.
7. [7] Cornuz, J., Gilbert, A., Pinget, C., McDonald, P., Slama, K., Salto, E., Paccaud, F., Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob. Control 15:3 (2006), 152–159.
8. [8] Goffin, J.R., Flanagan, W.M., Miller, A.B., Fitzgerald, N.R., Memon, S., Wolfson, M.C., Evans, W.K., Cost-effectiveness of lung cancer screening in Canada. JAMA Oncol. 1:6 (2015), 807–813.
9. [9] McMahon, P.M., Kong, C.Y., Bouzan, C., Weinstein, M.C., Cipriano, L.E., Tramontano, A.C., Johnson, B.E., Weeks, J.C., Gazelle, G.S., Cost-effectiveness of computed tomography screening for lung cancer in the United States. J. Thorac. Oncol. 6:11 (2011), 1841–1848.
10. [10] Villanti, A.C., Jiang, Y., Abrams, D.B., Pyenson, B.S., A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One, 8(8), 2013, e71379.
11. [11] Bach, P.B., Mirkin, J.N., Oliver, T.K., Azzoli, C.G., Berry, D.A., Brawley, O.W., Byers, T., Colditz, G.A., Gould, M.K., Jett, J.R., Sabichi, A.L., Smith-Bindman, R., Wood, D.E., Qaseem, A., Detterbeck, F.C., Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307:22 (2012), 2418–2429.
12. [12] Jaklitsch, M.T., Jacobson, F.L., Austin, J.H., Field, J.K., Jett, J.R., Keshavjee, S., MacMahon, H., Mulshine, J.L., Munden, R.F., Salgia, R., Strauss, G.M., Swanson, S.J., Travis, W.D., Sugarbaker, D.J., The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J. Thorac. Cardiovasc. Surg. 144:1 (2012), 33–38.
13. [13] H. Roberts, C. Walker-Dilks, K. Sivjee, Y.C. Ung, K. Yasufuku, A. Hey, N. Lewis, Screening high-risk populations for lung cancer, Program in Evidence-based Care Evidence-based Series No.: 15-10., Cancer Care Ontario, Toronto, 2013. https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=287881.
14. [14] Evans, W.K., Wolfson, M., Flanagan, W.M., Shin, J., Goffin, J.R., Asakawa, K., Earle, C., Mittmann, N., Fairclough, L., Fines, P., Gribble, S., Hoch, J., Hicks, C., Omariba, W.D.R., Ng, E., The evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model. Lung Cancer Manag. 1:1 (2012), 25–33.
15. [15] Flanagan, W.M., Evans, W.K., Fitzgerald, N.R., Goffin, J.R., Miller, A.B., Wolfson, M.C., Performance of the cancer risk management model lung cancer screening module. Health Rep. 26:5 (2015), 11–18.
16. [16] Public Health Agency of Canada, Organized Breast Cancer Screening Programs in Canada − Report on Program Performance in 2003 and 2004, Ottawa, (2008). http://www.phac-aspc.gc.ca/publicat/2008/obcsp-podcs-03-04/back-cont-eng.php.
17. [17] Tran, K., Asakawa, K., Cimon, K., Moulton, K., Kaunelis, D., Pipe, A., Selby, P., Pharmacologic-Based Strategies for Smoking Cessation: Clinical and Cost-Effectiveness Analyses. 2010, Canadian Agency for Drugs and Technologies in Health, Ottawa.
18. [18] Pastorino, U., Rossi, M., Rosato, V., Marchiano, A., Sverzellati, N., Morosi, C., Fabbri, A., Galeone, C., Negri, E., Sozzi, G., Pelosi, G., La Vecchia, C., Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur. J. Cancer Prev. 21:3 (2012), 308–315.
19. [19] Yousaf-Khan, U., van der Aalst, C., De Jong, P., Vliegenthart, R., Scholten, E., ten Haaf, K., Oudkerk, M., de Koning, H., Results of the fourth screening round of the NELSON lung cancer screening study. J. Thorac. Oncol. 10:9 (Suppl. 2) (2015), S190–S191.
20. [20] de Koning, H.J., Meza, R., Plevritis, S.K., ten Haaf, K., Munshi, V.N., Jeon, J., Erdogan, S.A., Kong, C.Y., Han, S.S., van Rosmalen, J., Choi, S.E., Miller, M., Moolgavkar, S., Pinsky, P.F., Berg, C.D., Berrington de Gonzalez, A., Black, W.C., Tammemagi, C.M., Hazelton, W.D., Feuer, E.J., McMahon, P.M., Benefits and Harms of Computed Tomography Lung Cancer Screening Programs for High-Risk Populations. AHRQ Publication No. 13-05196-EF-2. 2013, Agency for Healthcare Research and Quality, Rockville, MD.
21. [21] Black, W.C., Gareen, I.F., Soneji, S.S., Sicks, J.D., Keeler, E.B., Aberle, D.R., Naeim, A., Church, T.R., Silvestri, G.A., Gorelick, J., C. Gatsonis, T., National lung screening trial research, cost-effectiveness of CT screening in the national lung screening trial. N. Engl. J. Med. 371:19 (2014), 1793–1802.